Effect of teriflunomide on Epstein-Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study

被引：0

作者：

Gold, Julian ^{[1
,2
]}

Holden, David ^{[1
]}

Parratt, John ^{[3
,4
]}

Yiannikas, Con ^{[3
,4
]}

Ahmad, Raghib ^{[5
]}

Sedhom, Mamdouh ^{[6
]}

Giovannoni, Gavin ^{[1
]}

机构：

[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England

[2] Univ Sydney, Albion Ctr, Sch Med, Sydney, NSW, Australia

[3] Univ Sydney, Sydney, NSW, Australia

[4] Royal North Shore Hosp, Dept Neurol, Sydney, NSW, Australia

[5] Australian Digital Hlth Agcy, Sydney, NSW, Australia

[6] Sanofi Australia Pty Ltd, Macquarie Pk, NSW, Australia

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2022年 / 68卷

关键词：

Multiple sclerosis; Epstein -Barr virus; Teriflunomide; Relapsing -remitting multiple sclerosis; Infectious mononucleosis;

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Given its potential antiviral activity, we investigated the effect of teriflunomide on EBV in patients Methods: Saliva samples were collected at home and analysed for EBV DNA presence in patients with RRMS treated with teriflunomide for >= 3 months. Results: The proportion of patients with detectable EBV in the teriflunomide cohort was lower than in the reference cohorts. The proportion of samples with EBV DNA or shedding from teriflunomide-treated patients was reduced relative to each reference cohort (P<0.0001; >5.8 virus copies/mu L cut-off). Conclusion: This pilot study demonstrated the feasibility of at-home saliva sample collection and revealed a possible effect of teriflunomide on EBV shedding.

引用

页数：4

共 50 条

[1] Effect of teriflunomide on Epstein-Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study
Gold, Julian
Holden, David
Parratt, John
Yiannikas, Con
Ahmad, Raghib
Sedhom, Mamdouh
Giovannoni, Gavin
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
[2] Effect of teriflunomide on epstein-barr virus shedding in relapsing-remitting multiple sclerosis patients: outcomes from a real-world cohort study
Gold, J.
Holden, D.
Parratt, J.
Yiannikas, C.
Ahmad, R.
Giovannoni, G.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 277 - 278
[3] Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study
Zhang, Yao
Yin, Hexiang
Zhang, Dingding
Xu, Yan
Peng, Bin
Cui, Liying
JOURNAL OF NEUROLOGY, 2022, 269 (09) : 4808 - 4816
[4] Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study
Zhang, Y.
Yin, H.
Zhang, D.
Xu, Y.
Peng, B.
Cui, L.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 888 - 889
[5] Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study
Yao Zhang
Hexiang Yin
Dingding Zhang
Yan Xu
Bin Peng
Liying Cui
Journal of Neurology, 2022, 269 : 4808 - 4816
[6] Epstein-Barr virus antibodies in a sample of Egyptian patients with relapsing-remitting multiple sclerosis
Zamzam, Dina Mohammad AbdElgawad
Aziz, Azza Abdel Nasser Abdel
Fouad, Mohamad Mahmoud
Mahmoud, Aya Helal
Hafeez, Mohamed Aly Abdel
Swelam, Mahmoud Saad
Abou Steit, Alaa Mohamed
Khater, Shaimaa Sayed
Salah, Nouran Mohamed
Mahmoud, Amira ElHussien
Ahmed, Hend Ali
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP28 - NP28
[7] Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis
Boz, C.
Ozakbas, S.
Terzi, M.
Turkoglu, R.
Akman, G.
Efendi, H.
Akcali, A.
Tuncer, A.
Yuceyar, N.
Turan, O. F.
Soysal, A.
Koseoglu, M.
Balci, B. P.
Sevim, S.
Altintas, A.
Cilingir, V.
Demirkiran, M.
Kizilay, F.
Altunrende, B.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 327 - 328
[8] Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Meca-Lallana, Jose E.
Gonzalez, Jose M. Prieto
Rodriguez, Ana B. Caminero
Urtaza, Javier Olascoaga
Alonso, Ana M.
Ferreras, Eduardo Duran
Espinosa, Raul
Dotor, Julio
Romera, Mercedes
Luque, Adrian Ares
Ruiz, Domingo Perez
Calles, Carmen
Hernandez, Miguel A.
Garcia, Miguel Hervas
Rodriguez, Amelia Mendoza
Montero, Yasmina Berdei
Tellez, Nieves
Varo, Nicolas Herrera
Sotoca, Javier
Presas-Rodriguez, Silvia
Gutierrez, Luis A. Querol
Pujol, Mariona Hervas
Nadal, Jordi
Ozaeta, Gisela Martin
Lillo, Laura Gubieras
Yelamos, Sergio Martinez
Ramio-Torrenta, Lluis
Frechin, Javier Mallada
Benavides, Antonio Belenguer
Gascon-Gimenez, Francisco
Casanova, Bonaventura
Pascual, Lamberto Landete
Berenguer, Leticia
Navarro, Laura
Gutierrez, Montserrat Gomez
Duran, Carmen
Regal, Ana Rodriguez
Alvarez, Elena
Garcia-Estevez, Daniel A.
Real, Ana M. Lopez
Gonzalez, Miguel A. Llaneza
Sola, Maria E. Marzo
Sanchez-Menoyo, Jose L.
Oterino, Agustin
Gonzalez, Ramon Villaverde
Castillo-Trivino, Tamara
de Arcaya, Amaya
Llarena, Cristina
NEUROLOGY AND THERAPY, 2023, 12 (06) : 2177 - 2193
[9] Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study
Costa-Frossard Franca, Lucienne
Lallana, Virginia Meca
Labiano-Fontcuberta, Andres
Blasco, Rosario
Monreal, Enric
Gines, Maria Luisa Martinez
Aguirre, Clara
Munoz, Julia Sabin
de la Maza, Susana Sainz
Cuello, Juan Pablo
Diaz-Perez, Carolina
Garcia, Juan Luis Chico
Ros, Alberto Lozano
Jorge, Fernando Rodriguez
Martinez, SusanaMartinez
Dominguez, Jose Manuel Garcia
CNS DRUGS, 2024, 38 (04) : 291 - 302
[10] Quantitative Detection of Epstein-Barr Virus DNA in Cerebrospinal Fluid and Blood Samples of Patients with Relapsing-Remitting Multiple Sclerosis
Cocuzza, Clementina E.
Piazza, Fabrizio
Musumeci, Rosario
Oggioni, Davide
Andreoni, Simona
Gardinetti, Margherita
Fusco, Letizia
Frigo, Maura
Banfi, Paola
Rottoli, Maria R.
Confalonieri, Paolo
Rezzonico, Monica
Ferro, Maria T.
Cavaletti, Guido
PLOS ONE, 2014, 9 (04):

← 1 2 3 4 5 →